A phase I/II study of bevacizumab, irinotecan and erlotinib in children with progressive diffuse intrinsic pontine glioma.

Fatma E El-KhoulySophie E M Veldhuijzen van ZantenMarc H A JansenDewi P BakkerEsther Sanchez AliagaN Harry HendrikseW Peter VandertopDannis G van VuurdenGertjan J L Kaspers

Published in: Journal of neuro-oncology (2021)

Daily erlotinib is safe and well tolerated in doses up to 85 mg/m2 when combined with biweekly bevacizumab and irinotecan in children with progressive DIPG. Median OS of the study patients was longer than known form literature.

Keyphrases

multiple sclerosis
young adults
systematic review
end stage renal disease
newly diagnosed
physical activity
advanced non small cell lung cancer
prognostic factors
low grade